The University of Queensland Diamantina Institute, University of Queensland, Woolloongabba, Queensland, Australia.
Faculty of Medicine, University of Queensland, Woolloongabba, Queensland, Australia.
Curr Treat Options Oncol. 2020 Feb 3;21(1):9. doi: 10.1007/s11864-019-0697-3.
Recent studies have evidenced the potential of combining anti-EGFR therapies with anti-PD-1/PD-L1 checkpoint therapies. Both anti-EGFR and anti-PD-1/PD-L1 have been separately tested in the treatment of cutaneous SCC (cSCC). Here, we review recent data on EGFR in the context of cancer progression, as a prognostic and as a therapeutic target in cSCC. Anti-EGFR/checkpoint immunotherapy and other combination therapy approaches are discussed. With the advent of immunotherapy, EGFR is still a valid cSCC target.
最近的研究表明，将抗 EGFR 疗法与抗 PD-1/PD-L1 检查点疗法相结合具有潜力。抗 EGFR 和抗 PD-1/PD-L1 已分别在皮肤鳞状细胞癌（cSCC）的治疗中进行了测试。在这里，我们回顾了 EGFR 在癌症进展、预后和 cSCC 治疗靶点方面的最新数据。讨论了抗 EGFR/检查点免疫疗法和其他联合治疗方法。随着免疫疗法的出现，EGFR 仍然是一个有效的 cSCC 靶点。
